Management and outcome across the spectrum of high-risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk-score for secondary prevention.
clinical outcomes
high-risk populations
myocardial infarction
risk-stratification
temporal trends
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
14
07
2021
received:
30
04
2021
accepted:
02
08
2021
pubmed:
2
9
2021
medline:
10
11
2021
entrez:
1
9
2021
Statut:
ppublish
Résumé
Patients with myocardial infarction (MI) are at increased risk for recurrent cardiovascular events, yet some patients, such as the elderly and those with prior comorbidities, are particularly at the highest risk. Whether these patients benefit from contemporary management is not fully elucidated. Included were consecutive patients with MI who underwent percutaneous coronary intervention (PCI) in a large tertiary medical center. Patients were stratified according to the thrombolysis in myocardial infarction (TIMI) risk score for secondary prevention (TRS2°P) to high (TRS2°P = 3), very high (TRS2°P = 4), or extremely high-risk (TRS2°P = 5-9). Excluded were low and intermediate-risk patients (TRS2°P < 3). Outcomes included 30-day/1-year major adverse cardiac events (MACE) and 1-year mortality. Temporal trends were examined in the early (2004-2010) and late (2011-2016) time-periods. Among 2053 patients, 50% were high-risk, 30% very high-risk and 20% extremely high-risk. Extremely high-risk patients were older (age 74 ± 10 year) and had significant comorbidities (chronic kidney disease 68%, prior CABG 40%, heart failure 78%, peripheral artery disease 29%). Drug-eluting stents and potent antiplatelets were more commonly used over time in all risk-strata. Over time, 30-day MACE rates have decreased, mainly attributed to the very high (11.3% to 5.1%, p = .006) and extremely high-risk groups (15.9% to 8.0%, p = .016), but not the high-risk group, with similar quantitative results for 1-year MACE. The rates of 1-year mortality remained unchanged in either group. Within a particularly high-risk cohort of MI patients who underwent PCI, the implementation of guideline-recommended therapies has improved over time, with the highest-risk groups demonstrating the greatest benefit in outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with myocardial infarction (MI) are at increased risk for recurrent cardiovascular events, yet some patients, such as the elderly and those with prior comorbidities, are particularly at the highest risk. Whether these patients benefit from contemporary management is not fully elucidated.
METHODS
METHODS
Included were consecutive patients with MI who underwent percutaneous coronary intervention (PCI) in a large tertiary medical center. Patients were stratified according to the thrombolysis in myocardial infarction (TIMI) risk score for secondary prevention (TRS2°P) to high (TRS2°P = 3), very high (TRS2°P = 4), or extremely high-risk (TRS2°P = 5-9). Excluded were low and intermediate-risk patients (TRS2°P < 3). Outcomes included 30-day/1-year major adverse cardiac events (MACE) and 1-year mortality. Temporal trends were examined in the early (2004-2010) and late (2011-2016) time-periods.
RESULTS
RESULTS
Among 2053 patients, 50% were high-risk, 30% very high-risk and 20% extremely high-risk. Extremely high-risk patients were older (age 74 ± 10 year) and had significant comorbidities (chronic kidney disease 68%, prior CABG 40%, heart failure 78%, peripheral artery disease 29%). Drug-eluting stents and potent antiplatelets were more commonly used over time in all risk-strata. Over time, 30-day MACE rates have decreased, mainly attributed to the very high (11.3% to 5.1%, p = .006) and extremely high-risk groups (15.9% to 8.0%, p = .016), but not the high-risk group, with similar quantitative results for 1-year MACE. The rates of 1-year mortality remained unchanged in either group.
CONCLUSION
CONCLUSIONS
Within a particularly high-risk cohort of MI patients who underwent PCI, the implementation of guideline-recommended therapies has improved over time, with the highest-risk groups demonstrating the greatest benefit in outcomes.
Identifiants
pubmed: 34469003
doi: 10.1002/clc.23715
pmc: PMC8571543
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1535-1542Informations de copyright
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
Circulation. 2018 Apr 10;137(15):1571-1582
pubmed: 29263150
Heart. 2015 May 15;101(10):800-7
pubmed: 25801001
Curr Diab Rep. 2019 Jul 22;19(8):61
pubmed: 31332544
N Engl J Med. 2015 Jun 18;372(25):2387-97
pubmed: 26039521
Eur Heart J. 2007 Dec;28(23):2873-8
pubmed: 17982163
Circulation. 2007 May 15;115(19):2549-69
pubmed: 17502590
Eur J Prev Cardiol. 2019 Mar;26(4):411-419
pubmed: 30354737
Eur Heart J. 2016 Dec 21;37(48):3576-3584
pubmed: 27569841
Circulation. 2017 Dec 19;136(25):2440-2450
pubmed: 28972004
Eur Heart J Acute Cardiovasc Care. 2018 Apr;7(3):287-295
pubmed: 29504405
Ann Intern Med. 2004 Aug 3;141(3):186-95
pubmed: 15289215
J Am Coll Cardiol. 2011 Oct 18;58(17):1760-5
pubmed: 21996387
Lancet. 2012 Oct 13;380(9850):1317-24
pubmed: 22932716
Am J Med. 2020 Jul;133(7):839-847.e2
pubmed: 31982492
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Circulation. 2016 Jul 26;134(4):304-13
pubmed: 27440003
Heart. 2005 Mar;91(3):381-2
pubmed: 15710731
Diabetes Care. 2018 Mar;41(3):577-585
pubmed: 29196298
Clin Cardiol. 2021 Nov;44(11):1535-1542
pubmed: 34469003
Am Heart J. 2006 Jun;151(6):1205-13
pubmed: 16781220
Circulation. 2009 Sep 8;120(10):851-8
pubmed: 19704097
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Arch Cardiovasc Dis. 2019 Aug - Sep;112(8-9):459-468
pubmed: 31126738
J Am Coll Cardiol. 2017 Feb 28;69(8):911-921
pubmed: 28231942
J Am Heart Assoc. 2018 Sep 18;7(18):e009885
pubmed: 30371188